| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
-0.21 |
9e-11 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.2 |
1e-10 |
| mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.22 |
1e-09 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.21 |
2e-09 |
| mRNA |
SB-743921 |
CTRPv2 |
pan-cancer |
AAC |
-0.21 |
3e-09 |
| mRNA |
Mitomycin-C |
CTRPv2 |
pan-cancer |
AAC |
-0.2 |
3e-08 |
| mRNA |
ceranib-2 |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
4e-08 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
7e-08 |
| mRNA |
YK 4-279 |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
2e-07 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
3e-07 |